Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21014 | 0.90 | TP53BP1 (0.37) | NAMPTKDM4EMAPTTP53BP1SCN9A | |
| SCHEMBL30795512 | 0.88 | NAMPT (0.40) | NAMPTKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL21615 | 0.88 | NAMPT (0.40) | NAMPTKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL20906 | 0.84 | MLYCD (0.40) | MAPTSCN9A | |
| SCHEMBL21960 | 0.84 | MCHR1 (0.39) | NAMPTALDH1A1TP53BP1RAF1BRAF | |
| SCHEMBL23326 | 0.82 | HPGD (0.47) | KDM4EALDH1A1HPGDMAPTCYP2C9 | |
| SCHEMBL30795405 | 0.82 | HPGD (0.47) | KDM4EALDH1A1HPGDMAPTCYP2C9 | |
| SCHEMBL21336 | 0.81 | KCNQ3 (0.45) | KDM4EALDH1A1HPGDMAPTCYP2C9 | |
| SCHEMBL30795613 | 0.81 | KCNQ3 (0.45) | KDM4EALDH1A1HPGDMAPTCYP2C9 | |
| SCHEMBL23433 | 0.81 | DHODH (0.46) | KDM4EALDH1A1HPGDMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609083-B1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-02-25 | — | — | EP | claimed |
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2014-03-20 | — | — | US | claimed |
| US-8653101-B2 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2014-02-18 | — | — | US | claimed |
| EP-2609083-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2012-03-01 | — | — | US | claimed |
| WO-2012025236-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-9073862-B2 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| EP-2609083-B1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2014-03-20 | — | — | US | disclosed |
| US-8653101-B2 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-2609083-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2012025236-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | NAMPT 1348/4885KDM4E 505/4885ALDH1A1 3218/4885 |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | NAMPT 1348/4885KDM4E 505/4885ALDH1A1 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.